These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 16190745

  • 1. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
    Klabunde T, Wendt KU, Kadereit D, Brachvogel V, Burger HJ, Herling AW, Oikonomakos NG, Kosmopoulou MN, Schmoll D, Sarubbi E, von Roedern E, Schönafinger K, Defossa E.
    J Med Chem; 2005 Oct 06; 48(20):6178-93. PubMed ID: 16190745
    [Abstract] [Full Text] [Related]

  • 2. Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs.
    Oikonomakos NG, Kosmopoulou MN, Chrysina ED, Leonidas DD, Kostas ID, Wendt KU, Klabunde T, Defossa E.
    Protein Sci; 2005 Jul 06; 14(7):1760-71. PubMed ID: 15987904
    [Abstract] [Full Text] [Related]

  • 3. Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a.
    Onda K, Suzuki T, Shiraki R, Yonetoku Y, Negoro K, Momose K, Katayama N, Orita M, Yamaguchi T, Ohta M, Tsukamoto S.
    Bioorg Med Chem; 2008 May 15; 16(10):5452-64. PubMed ID: 18434170
    [Abstract] [Full Text] [Related]

  • 4. Integrated effects of multiple modulators on human liver glycogen phosphorylase a.
    Ercan-Fang N, Gannon MC, Rath VL, Treadway JL, Taylor MR, Nuttall FQ.
    Am J Physiol Endocrinol Metab; 2002 Jul 15; 283(1):E29-37. PubMed ID: 12067839
    [Abstract] [Full Text] [Related]

  • 5. Modeling aided design of potent glycogen phosphorylase inhibitors.
    Deng Q, Lu Z, Bohn J, Ellsworth KP, Myers RW, Geissler WM, Harris G, Willoughby CA, Chapman K, McKeever B, Mosley R.
    J Mol Graph Model; 2005 Apr 15; 23(5):457-64. PubMed ID: 15781188
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and pharmacological evaluation of bis-3-(3,4-dichlorophenyl)acrylamide derivatives as glycogen phosphorylase inhibitors.
    Onda K, Shiraki R, Yonetoku Y, Momose K, Katayama N, Orita M, Yamaguchi T, Ohta M, Tsukamoto S.
    Bioorg Med Chem; 2008 Sep 15; 16(18):8627-34. PubMed ID: 18723356
    [Abstract] [Full Text] [Related]

  • 7. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors.
    Gregus Z, Németi B.
    Toxicol Sci; 2007 Nov 15; 100(1):44-53. PubMed ID: 17693424
    [Abstract] [Full Text] [Related]

  • 8. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ, Greenhaff PL, MacInnes A, Timmons JA.
    Diabetes; 2006 Jun 15; 55(6):1855-61. PubMed ID: 16731853
    [Abstract] [Full Text] [Related]

  • 9. Kinetic analysis and modelling of the allosteric behaviour of liver and muscle glycogen phosphorylases.
    Cuadri-Tomé C, Barón C, Jara-Pérez V, Parody-Morreale A, Martinez JC, Cámara-Artigas A.
    J Mol Recognit; 2006 Jun 15; 19(5):451-7. PubMed ID: 16691548
    [Abstract] [Full Text] [Related]

  • 10. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 11. Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.
    Evans KA, Li YH, Coppo FT, Graybill TL, Cichy-Knight M, Patel M, Gale J, Li H, Thrall SH, Tew D, Tavares F, Thomson SA, Weiel JE, Boucheron JA, Clancy DC, Epperly AH, Golden PL.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4068-71. PubMed ID: 18554908
    [Abstract] [Full Text] [Related]

  • 12. N-(4-Substituted-benzoyl)-N'-(β-d-glucopyranosyl)ureas as inhibitors of glycogen phosphorylase: Synthesis and evaluation by kinetic, crystallographic, and molecular modelling methods.
    Nagy V, Felföldi N, Kónya B, Praly JP, Docsa T, Gergely P, Chrysina ED, Tiraidis C, Kosmopoulou MN, Alexacou KM, Konstantakaki M, Leonidas DD, Zographos SE, Oikonomakos NG, Kozmon S, Tvaroška I, Somsák L.
    Bioorg Med Chem; 2012 Mar 01; 20(5):1801-16. PubMed ID: 22325154
    [Abstract] [Full Text] [Related]

  • 13. Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies.
    Wen X, Sun H, Liu J, Cheng K, Zhang P, Zhang L, Hao J, Zhang L, Ni P, Zographos SE, Leonidas DD, Alexacou KM, Gimisis T, Hayes JM, Oikonomakos NG.
    J Med Chem; 2008 Jun 26; 51(12):3540-54. PubMed ID: 18517260
    [Abstract] [Full Text] [Related]

  • 14. Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site.
    Hampson LJ, Arden C, Agius L, Ganotidis M, Kosmopoulou MN, Tiraidis C, Elemes Y, Sakarellos C, Leonidas DD, Oikonomakos NG.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7835-45. PubMed ID: 16908161
    [Abstract] [Full Text] [Related]

  • 15. FR258900, a potential anti-hyperglycemic drug, binds at the allosteric site of glycogen phosphorylase.
    Tiraidis C, Alexacou KM, Zographos SE, Leonidas DD, Gimisis T, Oikonomakos NG.
    Protein Sci; 2007 Aug 01; 16(8):1773-82. PubMed ID: 17600143
    [Abstract] [Full Text] [Related]

  • 16. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1177-82. PubMed ID: 19138846
    [Abstract] [Full Text] [Related]

  • 17. Synthesis of a C-glucosylated cyclopropylamide and evaluation as a glycogen phosphorylase inhibitor.
    Bertus P, Szymoniak J, Jeanneau E, Docsa T, Gergely P, Praly JP, Vidal S.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4774-8. PubMed ID: 18701279
    [Abstract] [Full Text] [Related]

  • 18. Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
    Oikonomakos NG, Tiraidis C, Leonidas DD, Zographos SE, Kristiansen M, Jessen CU, Nørskov-Lauritsen L, Agius L.
    J Med Chem; 2006 Sep 21; 49(19):5687-701. PubMed ID: 16970395
    [Abstract] [Full Text] [Related]

  • 19. The crystal structure of human muscle glycogen phosphorylase a with bound glucose and AMP: an intermediate conformation with T-state and R-state features.
    Lukacs CM, Oikonomakos NG, Crowther RL, Hong LN, Kammlott RU, Levin W, Li S, Liu CM, Lucas-McGady D, Pietranico S, Reik L.
    Proteins; 2006 Jun 01; 63(4):1123-6. PubMed ID: 16523484
    [No Abstract] [Full Text] [Related]

  • 20. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q, Kasibhatla SR, Reddy KR, Jiang T, Reddy MR, Potter SC, Fujitaki JM, van Poelje PD, Huang J, Lipscomb WN, Erion MD.
    J Am Chem Soc; 2007 Dec 19; 129(50):15491-502. PubMed ID: 18041834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.